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The Language of Lysis:
A Proposal to Standardize the Nomenclature
Burton E. Sobel, MD
Burlington, Vermont
As the subtleties of pharmacologic thrombolysis and the
fibrinolytic cascade have been elucidated, many descriptive
terms have been applied. The published data demonstrate,
however, that despite good intentions, scientists and clini-
cians often use the same terms to mean different things.
Standardization of the nomenclature consistent with mo-
lecular properties of therapeutic agents would facilitate
assessments of diverse treatment regimens. One especially
troublesome ambiguity relates to fibrin binding and fibrin
selectivity of diverse approved and investigational fibrino-
lytic agents. An appropriate set of definitions follows:
“Fibrin binding” refers to the binding of a protein or
other moiety to fibrin.
“Fibrin selectivity” refers to a plasminogen activator’s
increased enzymatic activity in the presence of fibrin as
compared with activity in its absence.
“Clot selectivity” refers to the clinically relevant effect of
fibrin selectivity—the extent to which a lytic drug activates
clot-bound plasminogen to form plasmin, as opposed to
acting on circulating plasminogen.
The rationale for these definitions is as follows. Fibrino-
lytic drugs (also called thrombolytic agents or lytic agents)
that are not clot-selective convert to plasmin the plasmin-
ogen that is freely circulating in the blood. This newly
created plasmin can cleave the lysine-binding sites on fibrin
that facilitate docking of plasminogen and plasminogen
activators on the fibrin clot. Thus, plasmin can paradoxically
inhibit fibrinolysis. In contrast, clot- and fibrin-selective
agents (e.g., native tissue-type plasminogen activator [t-PA]
and its recombinant form, alteplase) convert free plasmin-
ogen to plasmin only minimally. Instead, they preferentially
activate clot-bound plasminogen to form plasmin that is
already bound to fibrin in lysine-binding sites. As the clot
dissolves, new lysine-binding sites are exposed. In the absence
of circulating plasmin, they remain available to bind plasmin-
ogen and t-PA, thereby facilitating continuing clot lysis.
Administration of non–clot-selective lytic agents effec-
tively initiates clot lysis, but the subsequent activation of free
plasminogen yields plasminemia, which results in cleavage
of several components of the coagulation cascade, rendering
the blood hypercoagulable even in the presence of an
anticoagulant such as heparin.
In the context of these principles, it is useful to categorize
the available and investigational thrombolytic agents with
respect to clot selectivity. The first two lytic agents that were
available—streptokinase and urokinase—activate circulating
plasminogen and exhibit no clot selectivity.
The second-generation agent, t-PA, is a recombinant
form of the native molecule and exhibits fibrin and clot
selectivity. Saruplase, although inherently fibrin-selective, is
not clot selective in vivo because it is converted by plasmin
to urokinase, a two-chain molecule that is not fibrin-selective
(1). Reteplase (rPA) and lanoteplase (nPA) have very little clot
selectivity as a consequence of their structural features (both are
deletion mutants of the natural t-PA molecule).
The kringle-1, finger and epidermal growth factor (EGF)
domains are the domains in the native t-PA molecule that
participate in fibrin binding (2). Therefore, plasminogen
activators such as lanoteplase and reteplase, both of which
entail deletions in these domains, exhibit decreased fibrin
binding as compared with that of t-PA. Lanoteplase, which
lacks the EGF domain, binds less avidly to fibrin, associates
less with fibrin and therefore has less clot selectivity (3).
Reteplase lacks the kringle-1, EGF and finger domains, and
therefore it too exhibits little clot selectivity (4). In contrast,
both the third-generation agents staphylokinase and TNK-
t-PA exhibit strong clot selectivity (5).
Although clot selectivity per se is not measured in clinical
trials, the molecular structure of the various thrombolytic
agents is certainly likely to influence outcome in such trials.
For example, in the Thrombolysis in Myocardial Infarction
(TIMI-1) clinical trial, the clot-selective agent t-PA was
more effective than the non–clot-selective agent streptoki-
nase (6). In the Global Utilization of Streptokinase and
TPA for Occluded arteries study (GUSTO-I), a 14%
relative risk reduction in “early” mortality was seen with
clot-selective t-PA versus streptokinase (7).
The increased benefit of clot-selective agents such as
t-PA may be masked in clinical trials by delays in the time
to treatment. In GUSTO-I, the relative risk reduction was
substantially greater in patients treated very early (i.e.,
within 1 to 2 h of symptom onset). In clinical trials that
enroll many patients more than 2 or 3 h after onset of
symptoms, agents with distinct biologic differences will
produce similar outcomes because most of the benefit that
could have been conferred with early treatment will haveFrom the Department of Medicine, University of Vermont, Burlington, Vermont.
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been lost. In contrast, true differences between drugs will be
much more apparent with respect to outcomes in trials in
which many patients are enrolled early.
In summary, molecular variations in thrombolytic agents
are germane to their biologic properties and clinical effects.
As additional fibrinolytic agents become available, it will be
important to consider them in the context of fibrin binding,
fibrin selectivity and clot selectivity. To avoid confusion,
these terms should be applied with care and consistency.
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